The 1st International Online Conference on Personalized Medicine
The 1st International Online Conference on Personalized Medicine
Part of the International Online Conference on Personalized Medicine series
Event's Timezone: Central European TimeAbstract Submission Deadline
11 August 2025
Abstract Acceptance Notification
12 September 2025
Registration Deadline
24 October 2025
Personalized Medicine, Personalized Preventive Medicine, Pharmacogenetics Omics and Informatics, Precision Oncology, Disease Mechanisms Personalized, Personalized Therapy, Personalized Diagnostics
Abstract Submission Deadline is Closed.
Thank you for submitting your abstract to the IOCPM 2025.
The abstract acceptance notification will be sent by 12 September 2025.
Registration remains open. Secure your spot and join us for a stimulating conference. Register for free HERE.
For any inquiries, please contact us at iocpm2025@mdpi.com.
Welcome from the Chair
Dear Colleagues,
Please join us at the 1st International Online Conference on Personalized Medicine (IOCPM 2025), which will be hosted online from 29 to 31 October 2025.
Personalization to the individual’s specific condition has been integral to clinical medicine since ancient times; however, the possibilities of a truly personal approach to diagnosis and therapy have been limited. Now, in the most recent decade, interest in Personalized Medicine has exploded, with over 45,000 publications integrating advances in all biomedical sciences in every branch of medicine, toward the goals of more individualized diagnosis, therapy, and continuing care.
IOCPM 2025 will be a major forum for physicians and scientists, worldwide, to present and discuss advances at the frontier of Personalized Medicine.
IOCPM 2025 is designed to encompass the breadth and depth of topics currently most relevant to Personalized Medicine. Presentations will be channeled into six sessions:
S1. Mechanisms of Diseases;
S2. Personalized Preventive Medicine;
S3. Diagnostics in Personalized Medicine;
S4. Personalized Therapy in Clinical Medicine;
S5. Pharmacogenetics, Omics, and Informatics;
S6. Precision Oncology.
S2. Personalized Preventive Medicine;
S3. Diagnostics in Personalized Medicine;
S4. Personalized Therapy in Clinical Medicine;
S5. Pharmacogenetics, Omics, and Informatics;
S6. Precision Oncology.
IOCPM 2025 will enable you to share and discuss your most recent research findings in Personalized Medicine with the vibrant global community of scientists and physicians in the field.
IOCPM 2025 will make your presentation accessible to hundreds of researchers worldwide, with the active engagement of the audience in question-and-answer sessions and discussion groups that will take place online.
The conference committee will review all submitted abstracts. The authors of accepted contributions will have their work displayed in an abstract collection. Following the conference, outstanding contributions will be invited to be submitted as a full-length paper for publication in the Journal of Personalized Medicine.
IOCPM 2025 promises to be a most exciting conference, which we anticipate will become a transformative landmark in Personalized Medicine. We hope you will join us, present your work, contribute to discussions, and meet new colleagues. Together at IOCPM 2025, we will shape the future of Personalized Medicine.
Best wishes,
Prof. Dr. Kenneth P. H. Pritzker
MD, FRCPC
Professor Emeritus,
Laboratory Medicine and Pathobiology;
Surgery Temerty Faculty of Medicine,
University of Toronto, Toronto, Canada
Conference Chair of the 1st International Online Conference on Personalized Medicine
Prof. Dr. Kenneth P. H. Pritzker
MD, FRCPC
Professor Emeritus,
Laboratory Medicine and Pathobiology;
Surgery Temerty Faculty of Medicine,
University of Toronto, Toronto, Canada
Conference Chair of the 1st International Online Conference on Personalized Medicine
Program Overview
| 29 Oct Morning | 30 Oct Morning | 31 Oct Morning |
|
Session 5. Pharmacogenetics, Omics, and Informatics |
Session 4. Personalized Therapy in Clinical Medicine |
Session 5. Pharmacogenetics, Omics, and Informatics |
| 29 Oct Afternoon | 30 Oct Afternoon | 31 Oct Afternoon |
|
Session 1. Mechanisms of Diseases Session 2. Personalized Preventive Medicine |
Session 3. Diagnostics in Personalized Medicine |
Session 6. Precision Oncology |
Event Chair
Laboratory Medicine and Pathobiology; Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Bio
Dr. Pritzker is Professor Emeritus in the Department of Laboratory Medicine and Pathobiology; Department of Surgery, Temerty Faculty of Medicine, and the Institute of Biomedical Engineering, University of Toronto and is Honorary Staff , Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto. Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto from 1986 to 2008. With over 290 scientific publications and 27 book chapters, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology. Dr. Pritzker served on the External Advisory Board, Institute of Microstructural Sciences, National Research Council of Canada, 2005-2011. Dr. Pritzker serves as editor-in-chief, Journal of Personalized Medicine.
Dr. Pritzker is Professor Emeritus in the Department of Laboratory Medicine and Pathobiology; Department of Surgery, Temerty Faculty of Medicine, and the Institute of Biomedical Engineering, University of Toronto and is Honorary Staff , Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto. Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto from 1986 to 2008. With over 290 scientific publications and 27 book chapters, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology. Dr. Pritzker served on the External Advisory Board, Institute of Microstructural Sciences, National Research Council of Canada, 2005-2011. Dr. Pritzker serves as editor-in-chief, Journal of Personalized Medicine.
Session Chairs
Dr. Seungil Ro
Department of Physiology & Cell Biology, University of Nevada, Reno, School of Medicine, Nevada, USA
Session name
S1. Mechanisms of Diseases
S1. Mechanisms of Diseases
Keywords
diabetes; gastrointestinal disorders; smooth muscle; microRNAs; non-coding RNA
diabetes; gastrointestinal disorders; smooth muscle; microRNAs; non-coding RNA
Bio
Dr. Seungil Ro has published 75 articles, including in several high-impact journals, on genetic and epigenetic regulation in diabetes, gastrointestinal disorders, and cancers. He holds seven U.S. and international patents for treatments targeting diabetes and gastrointestinal dysmotility and has secured over $12 million in research funding. As the founder of RosVivo Therapeutics, Dr. Ro has pioneered the development of therapeutic microRNAs for diabetes, obesity, fatty liver disease, and gastrointestinal dysmotility. He has delivered over 80 presentations at international and domestic institutions, served as a panel reviewer for NIH and international grant programs, and contributed as an editor for multiple peer-reviewed journals.
Dr. Seungil Ro has published 75 articles, including in several high-impact journals, on genetic and epigenetic regulation in diabetes, gastrointestinal disorders, and cancers. He holds seven U.S. and international patents for treatments targeting diabetes and gastrointestinal dysmotility and has secured over $12 million in research funding. As the founder of RosVivo Therapeutics, Dr. Ro has pioneered the development of therapeutic microRNAs for diabetes, obesity, fatty liver disease, and gastrointestinal dysmotility. He has delivered over 80 presentations at international and domestic institutions, served as a panel reviewer for NIH and international grant programs, and contributed as an editor for multiple peer-reviewed journals.
Dr. Latha Palaniappan
Stanford Concierge and Executive Medicine, Stanford University, California, USA
Session name
S2. Personalized Preventive Medicine
S2. Personalized Preventive Medicine
Keywords
Pharmacogenomics (PgX); Implementation Science; Racial/Ethnic Minorities; Chronic Disease and Prevention; Cardiovascular Disease; Diabetes
Pharmacogenomics (PgX); Implementation Science; Racial/Ethnic Minorities; Chronic Disease and Prevention; Cardiovascular Disease; Diabetes
Bio
Latha Palaniappan MD, MS, is an internist, and clinical and population researcher. Her research has focused on the study of diverse populations, chronic disease and prevention, and seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities. She was awarded a Stanford Impact Labs Leave in Service to pursue chronic disease prevention in India for Social Good. She is the Faculty co-Director of Stanford Biobank, designed to accelerate translatable scientific discoveries and co-founder for the Stanford Center for Asian American, Native Hawaiian and Pacific Islander Health Research and Education (CARE). CARE has established health related research collaborations in Asia, including student exchange programs in Hong Kong and Vietnam, and research collaborations in India, Japan, and Singapore. She has recently received a Fulbright Future Scholar Award and worked with the Commonwealth Scientific and Industrial Research Organization on implementation of Precision Health in Australia.
Latha Palaniappan MD, MS, is an internist, and clinical and population researcher. Her research has focused on the study of diverse populations, chronic disease and prevention, and seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities. She was awarded a Stanford Impact Labs Leave in Service to pursue chronic disease prevention in India for Social Good. She is the Faculty co-Director of Stanford Biobank, designed to accelerate translatable scientific discoveries and co-founder for the Stanford Center for Asian American, Native Hawaiian and Pacific Islander Health Research and Education (CARE). CARE has established health related research collaborations in Asia, including student exchange programs in Hong Kong and Vietnam, and research collaborations in India, Japan, and Singapore. She has recently received a Fulbright Future Scholar Award and worked with the Commonwealth Scientific and Industrial Research Organization on implementation of Precision Health in Australia.
Dr. Kenneth Pritzker
Laboratory Medicine and Pathobiology; Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Session name
S3. Diagnostics in Personalized Medicine
S3. Diagnostics in Personalized Medicine
Keywords
Personalized Medicine; Laboratory diagnostics; Arthritis; Biomineralization
Personalized Medicine; Laboratory diagnostics; Arthritis; Biomineralization
Bio
Dr. Pritzker is Professor Emeritus in the Department of Laboratory Medicine and Pathobiology; Department of Surgery, Temerty Faculty of Medicine, and the Institute of Biomedical Engineering, University of Toronto and is Honorary Staff , Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto. Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto from 1986 to 2008. With over 290 scientific publications and 27 book chapters, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology. Dr. Pritzker served on the External Advisory Board, Institute of Microstructural Sciences, National Research Council of Canada, 2005-2011. Dr. Pritzker serves as editor-in-chief, Journal of Personalized Medicine.
Dr. Pritzker is Professor Emeritus in the Department of Laboratory Medicine and Pathobiology; Department of Surgery, Temerty Faculty of Medicine, and the Institute of Biomedical Engineering, University of Toronto and is Honorary Staff , Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto. Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto from 1986 to 2008. With over 290 scientific publications and 27 book chapters, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology. Dr. Pritzker served on the External Advisory Board, Institute of Microstructural Sciences, National Research Council of Canada, 2005-2011. Dr. Pritzker serves as editor-in-chief, Journal of Personalized Medicine.
Dr. Taulant Muka
Epistudia, Bern, Switzerland
Session name
S4. Personalized Therapy in Clinical Medicine
S4. Personalized Therapy in Clinical Medicine
Keywords
evidence-based medicine; evidence synthesis; systematic reviews and meta-analyses; cardiometabolic health; sex differences in medicine; iron and estrogen; epidemiology; research methodology; healthcare Innovation; health disparities
evidence-based medicine; evidence synthesis; systematic reviews and meta-analyses; cardiometabolic health; sex differences in medicine; iron and estrogen; epidemiology; research methodology; healthcare Innovation; health disparities
Bio
Dr. Taulant Muka is among the top 2% of the world’s most influential scientists, with over 180 peer-reviewed publications and extensive expertise in evidence-based medicine and public health. As CEO of Epistudia, he pioneers education innovation through AI and e-learning tools. Dr. Muka's academic journey spans prestigious institutions like University of Bern, Erasmus, Cambridge, Harvard, and Stanford, with research focusing on cardiometabolic health, sex differences, and evidence synthesis. His work has been featured in global media outlets like BBC, CNN, and The New York Times.
Dr. Taulant Muka is among the top 2% of the world’s most influential scientists, with over 180 peer-reviewed publications and extensive expertise in evidence-based medicine and public health. As CEO of Epistudia, he pioneers education innovation through AI and e-learning tools. Dr. Muka's academic journey spans prestigious institutions like University of Bern, Erasmus, Cambridge, Harvard, and Stanford, with research focusing on cardiometabolic health, sex differences, and evidence synthesis. His work has been featured in global media outlets like BBC, CNN, and The New York Times.
Prof. Enrico Mini
Emeritus Professor of Medical Oncology, Department of Health Sciences, University of Florence, Florence, Italy
Session name
Pharmacogenetics, Omics, and Informatics
Pharmacogenetics, Omics, and Informatics
Keywords
Gastrointestinal Cancers; Tumor Drug Resistance; Cancer Pharmacogenomics and Pharmacogenetics; Anticancer Drug Synergism
Gastrointestinal Cancers; Tumor Drug Resistance; Cancer Pharmacogenomics and Pharmacogenetics; Anticancer Drug Synergism
Bio
Prof. Mini is an Emeritus Professor of Medical Oncology at the Department of Health Sciences, University of Florence (Italy). His research interests comprise the mechanisms of tumor drug resistance, in particular to antimetabolites and metal-based drugs, cancer pharmacogenomics and pharmacogenetics, and controlled clinical trials in gastrointestinal cancers. His studies have contributed to the advancement of knowledge in the field of biochemical bases of anticancer drug synergism and molecular bases of anticancer drug resistance. Prof. Mini is the author of more than 190 original articles in international peer reviewed journals and about 80 reviews, editorials, book chapters, and letters. He has given over 260 invited talks at national and international conferences and seminars at Italian and foreign universities and has presented more than 350 communications at scientific congresses. In recognition of his outstanding achievements, Prof. Mini has received various awards and recognitions and grants for his research results, including the Leukemia Society of America Special Fellow Award in 1982, the Lady Tata Memorial Trust Award, the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award in 1988 and in 2019 the 'International Society of Antimicrobial Chemotherapy (ISAC) Fellow Award (London). Prof. Mini has also held prestigious positions in various scientific societies. He is currently the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology
Prof. Mini is an Emeritus Professor of Medical Oncology at the Department of Health Sciences, University of Florence (Italy). His research interests comprise the mechanisms of tumor drug resistance, in particular to antimetabolites and metal-based drugs, cancer pharmacogenomics and pharmacogenetics, and controlled clinical trials in gastrointestinal cancers. His studies have contributed to the advancement of knowledge in the field of biochemical bases of anticancer drug synergism and molecular bases of anticancer drug resistance. Prof. Mini is the author of more than 190 original articles in international peer reviewed journals and about 80 reviews, editorials, book chapters, and letters. He has given over 260 invited talks at national and international conferences and seminars at Italian and foreign universities and has presented more than 350 communications at scientific congresses. In recognition of his outstanding achievements, Prof. Mini has received various awards and recognitions and grants for his research results, including the Leukemia Society of America Special Fellow Award in 1982, the Lady Tata Memorial Trust Award, the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award in 1988 and in 2019 the 'International Society of Antimicrobial Chemotherapy (ISAC) Fellow Award (London). Prof. Mini has also held prestigious positions in various scientific societies. He is currently the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology
Dr. Masakazu Kamata
Department of Microbiology, Heersink School of Medicine, University of Alabama, Birmingham, AL, USA
Session name
S6. Precision Oncology
S6. Precision Oncology
Keywords
Cancer immunotherapy, HIV immunotherapy, CAR-T, CAR-Mac, bidirectional antibody, immunomodulator
Cancer immunotherapy, HIV immunotherapy, CAR-T, CAR-Mac, bidirectional antibody, immunomodulator
Bio
Our research team is focused on creating a clinically relevant animal model to enhance our understanding of biology and develop new therapies for metastatic cancer and HIV-infected cells. Each model aims to investigate the complex mechanisms of cancer or HIV biology and their treatment effects at the molecular scale. Uncovering specific pathways has led to the emergence of new pharmaceuticals, such as antibody-drug conjugates, immunomodulators, and chimeric antigen receptors.
Our research team is focused on creating a clinically relevant animal model to enhance our understanding of biology and develop new therapies for metastatic cancer and HIV-infected cells. Each model aims to investigate the complex mechanisms of cancer or HIV biology and their treatment effects at the molecular scale. Uncovering specific pathways has led to the emergence of new pharmaceuticals, such as antibody-drug conjugates, immunomodulators, and chimeric antigen receptors.
Event Committee
Centre for Health Technology, Faculty of Health, University of Plymouth, UK
Bio
Dr. Shang-Ming Zhou is a distinguished Professor of eHealth at the University of Plymouth, UK, where he serves as the Deputy Director of the Centre for Health Technology in the Faculty of Health: Medicine, Dentistry and Human Sciences. Dr. Zhou's work focuses on AI-driven personalized medicine, health informatics, health data science, disease phenotyping, risk stratification, polypharmacy, multimorbidity, and public health research. He leads different projects, advancing healthcare data analytics for patient-centric innovations.
Dr. Shang-Ming Zhou is a distinguished Professor of eHealth at the University of Plymouth, UK, where he serves as the Deputy Director of the Centre for Health Technology in the Faculty of Health: Medicine, Dentistry and Human Sciences. Dr. Zhou's work focuses on AI-driven personalized medicine, health informatics, health data science, disease phenotyping, risk stratification, polypharmacy, multimorbidity, and public health research. He leads different projects, advancing healthcare data analytics for patient-centric innovations.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy,
Scleroderma Unit, Division of Rheumatology, AO Careggi Hospital, Florence, Italy
Bio
Silvia Bellando Randone is an Associate Professor at the University of Florence’s Department of Experimental and Clinical Medicine. She specializes in Rheumatology, with clinical expertise in systemic sclerosis, rheumatoid arthritis, spondyloarthritis, myositis, and Sjögren’s syndrome, focusing on early diagnosis and personalized treatments. She leads the Scleroderma Unit at Careggi University Hospital. Her research focuses on the early diagnosis of rheumatic diseases, particularly systemic sclerosis, exploring the microbiota’s role in disease pathogenesis and identifying biomarkers for disease progression and treatment response. She is a member of national and international research organizations like SIR, EUSTAR, and GRAPPA. Dr. Bellando Randone teaches in various programs at the University of Florence and serves on the PhD Faculty Board in Clinical Sciences. She has authored over 160 scientific papers and regularly speaks and moderates at national and international rheumatology congresses
Silvia Bellando Randone is an Associate Professor at the University of Florence’s Department of Experimental and Clinical Medicine. She specializes in Rheumatology, with clinical expertise in systemic sclerosis, rheumatoid arthritis, spondyloarthritis, myositis, and Sjögren’s syndrome, focusing on early diagnosis and personalized treatments. She leads the Scleroderma Unit at Careggi University Hospital. Her research focuses on the early diagnosis of rheumatic diseases, particularly systemic sclerosis, exploring the microbiota’s role in disease pathogenesis and identifying biomarkers for disease progression and treatment response. She is a member of national and international research organizations like SIR, EUSTAR, and GRAPPA. Dr. Bellando Randone teaches in various programs at the University of Florence and serves on the PhD Faculty Board in Clinical Sciences. She has authored over 160 scientific papers and regularly speaks and moderates at national and international rheumatology congresses
Bio
Dr Duddy is Senior Lecturer in Stratified Medicine (Bioinformatics) at the Personalised Medicine Centre in Ulster University’s School of Medicine. As co-lead of the neuromuscular research team, he builds on a diverse background in molecular & cellular biology, biochemistry, and bioinformatics, to integrate systems biology data analytics into the team’s cell and molecular studies. This integrative approach has led the team to investigate the role of secretory vesicles in neuromuscular and neurodegenerative disorders, and to their identification of vesicles as a source of neuronal toxicity. Dr Duddy’s commitment to neuromuscular research and wider interest in Personalised Medicine derive from losing his brother to Duchenne muscular dystrophy.
Dr Duddy is Senior Lecturer in Stratified Medicine (Bioinformatics) at the Personalised Medicine Centre in Ulster University’s School of Medicine. As co-lead of the neuromuscular research team, he builds on a diverse background in molecular & cellular biology, biochemistry, and bioinformatics, to integrate systems biology data analytics into the team’s cell and molecular studies. This integrative approach has led the team to investigate the role of secretory vesicles in neuromuscular and neurodegenerative disorders, and to their identification of vesicles as a source of neuronal toxicity. Dr Duddy’s commitment to neuromuscular research and wider interest in Personalised Medicine derive from losing his brother to Duchenne muscular dystrophy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, School of Specialization in General Surgery, Plastic Surgery and Oncology, Catholic University of the Sacred Heart, Rome, Italy
Bio
Professor Gianluca Franceschini is a Full Professor of General Surgery and Head of the Breast Unit at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, Italy. He has performed over 4,000 breast cancer surgeries in the past decade and authored over 200 scientific papers and 15 textbook chapters (Orcid ID: 0000-0002-2950-3395; Scopus Author ID: 23027478400). He is a professor at the School of Specialization in General Surgery, Plastic Surgery, and Oncology at the Catholic University of Rome and has been a Full Member of the Teaching College for the university's PhD programs since 2010. He also directs the Master’s programs in "Breast Nurse" and "Integrated Therapies in Female Oncological Diseases" at the Catholic University of the Sacred Heart since 2024. He acts as Scientific Director of several research projects on the surgical treatment of breast cancers, funded through competitive grants with peer review. He is also Principal Investigator of several scientific trials commissioned by the Fondazione Policlinico Universitario Agostino Gemelli IRCCS of Rome and the Scientific Director (Local Investigator) of several international multicenter trials on the surgical treatment of breast neoplasms. Being also on the editorial board for several scientific journals, his work earned him a Medal from The Royal College of Radiologists in 2010 and the Awards for High-Quality Publications from the Catholic University in 2020. He created the "ADAPTED01 Breast Cancer" app and is a founding partner of Susan G. Komen Italia. He has served as a Research and Teaching Fellow at HopeXChange Medical Centre in Kumasi, Ghana, and is a registered expert in REPRISE. A permanent member of the College of Italian Breast Surgeons, he was included in the World's Top 2% Scientists ranking by Stanford University and Elsevier in 2021.
Professor Gianluca Franceschini is a Full Professor of General Surgery and Head of the Breast Unit at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Rome, Italy. He has performed over 4,000 breast cancer surgeries in the past decade and authored over 200 scientific papers and 15 textbook chapters (Orcid ID: 0000-0002-2950-3395; Scopus Author ID: 23027478400). He is a professor at the School of Specialization in General Surgery, Plastic Surgery, and Oncology at the Catholic University of Rome and has been a Full Member of the Teaching College for the university's PhD programs since 2010. He also directs the Master’s programs in "Breast Nurse" and "Integrated Therapies in Female Oncological Diseases" at the Catholic University of the Sacred Heart since 2024. He acts as Scientific Director of several research projects on the surgical treatment of breast cancers, funded through competitive grants with peer review. He is also Principal Investigator of several scientific trials commissioned by the Fondazione Policlinico Universitario Agostino Gemelli IRCCS of Rome and the Scientific Director (Local Investigator) of several international multicenter trials on the surgical treatment of breast neoplasms. Being also on the editorial board for several scientific journals, his work earned him a Medal from The Royal College of Radiologists in 2010 and the Awards for High-Quality Publications from the Catholic University in 2020. He created the "ADAPTED01 Breast Cancer" app and is a founding partner of Susan G. Komen Italia. He has served as a Research and Teaching Fellow at HopeXChange Medical Centre in Kumasi, Ghana, and is a registered expert in REPRISE. A permanent member of the College of Italian Breast Surgeons, he was included in the World's Top 2% Scientists ranking by Stanford University and Elsevier in 2021.
Research Keywords
breast cancer; breast surgery; oncoplastic surgery; breast treatment
breast cancer; breast surgery; oncoplastic surgery; breast treatment
Dr. Josefina Rodrigues Cernadas
Allergy and Clinical Immunology Department, Centro Hospitalar Universitário São João, Porto, Portugal
Department of Medicine and Surgery, University of Salerno, Fisciano, Italy
Center of Basic Research, Biomedical Research Foundation, Academy of Athens, Athens, Greece
Department of Molecular and Precision Medicine, Pennsylvania State College of Medicine, Hershey, PA, USA
Bio
Raghu Sinha, PhD is a Professor of Molecular and Precision Medicine, Penn State College of Medicine, Hershey, Pennsylvania. He is an expert in cancer chemoprevention, cancer therapy and proteomics. His research focuses on studying mechanisms of breast, prostate and pancreatic tumor growth inhibition by organoselenium compounds, impact of dietary sulfur amino acids in animal cancer models and healthy humans, effects of tobacco products on lung epithelial cells, cancer systems biology, protein-protein interactions, and multi-omics approaches for identifying diagnostic and prognostic cancer biomarkers as well as drug repurposing strategies. He has mentored high school, undergraduate and graduate students, and post-doctoral fellows.
Raghu Sinha, PhD is a Professor of Molecular and Precision Medicine, Penn State College of Medicine, Hershey, Pennsylvania. He is an expert in cancer chemoprevention, cancer therapy and proteomics. His research focuses on studying mechanisms of breast, prostate and pancreatic tumor growth inhibition by organoselenium compounds, impact of dietary sulfur amino acids in animal cancer models and healthy humans, effects of tobacco products on lung epithelial cells, cancer systems biology, protein-protein interactions, and multi-omics approaches for identifying diagnostic and prognostic cancer biomarkers as well as drug repurposing strategies. He has mentored high school, undergraduate and graduate students, and post-doctoral fellows.
Research Keywords
chemoprevention, cancer diagnostics, cancer therapy, oxidative stress, proteomics, systems biology
chemoprevention, cancer diagnostics, cancer therapy, oxidative stress, proteomics, systems biology
Department of Psychiatry, Texas Tech University Health Sciences Center, Permian Basin, Odessa, USA
Bio
Dr Badgaiyan is Professor and Chairman of the Department of Psychiatry at Texas Tech University Health Sciences Center. He completed psychiatry residency training at Harvard Medical School and worked as a member of faculty at Harvard Medical School for over 10 years. He then moved to other academic centers to gain experience of leadership. He worked as the Chairman of psychiatry department at a Mt Sinai Hospital in New York city, Chief of Psychiatry at South Texas Veterans Healthcare System in San Antonio and Chairman of Psychiatry at Case Western Reserve University before moving back to Texas. As a leader he was instrumental in growing academic and clinical activities of departments and made the departments financially viable. He is international expert in neuroimaging and is widely known for developing a unique brain imaging technique for detection, mapping and measurement of neurotransmitters released acutely in the human brain during the brain processing of mental activities. His research is focused primarily on addiction and dysregulation of dopamine neurotransmission in psychiatric and neurological conditions. Dr Badgaiyan has received several prizes and awards including the prestigious Solomon Prize of Harvard University and B.K. Anand National Research Prize in India. Dr Badgaiyan is recipient of many multimillion dollar research grants. He has published over 300 peer-reviewed scientific papers and works as the Editor-in-Chief of several per-reviewed international journals. He is the author of a popular book, ‘Neuroscience of the Nonconscious Mind’ published by Elsevier/Academic Press.
Dr Badgaiyan is Professor and Chairman of the Department of Psychiatry at Texas Tech University Health Sciences Center. He completed psychiatry residency training at Harvard Medical School and worked as a member of faculty at Harvard Medical School for over 10 years. He then moved to other academic centers to gain experience of leadership. He worked as the Chairman of psychiatry department at a Mt Sinai Hospital in New York city, Chief of Psychiatry at South Texas Veterans Healthcare System in San Antonio and Chairman of Psychiatry at Case Western Reserve University before moving back to Texas. As a leader he was instrumental in growing academic and clinical activities of departments and made the departments financially viable. He is international expert in neuroimaging and is widely known for developing a unique brain imaging technique for detection, mapping and measurement of neurotransmitters released acutely in the human brain during the brain processing of mental activities. His research is focused primarily on addiction and dysregulation of dopamine neurotransmission in psychiatric and neurological conditions. Dr Badgaiyan has received several prizes and awards including the prestigious Solomon Prize of Harvard University and B.K. Anand National Research Prize in India. Dr Badgaiyan is recipient of many multimillion dollar research grants. He has published over 300 peer-reviewed scientific papers and works as the Editor-in-Chief of several per-reviewed international journals. He is the author of a popular book, ‘Neuroscience of the Nonconscious Mind’ published by Elsevier/Academic Press.
Department of Pediatrics, Luton & Dunstable University Hospital NHS Foundation Trust, Lewsey Road, Luton, UK
Bio
Dr. med. Michael Eisenhut has been an editor of the Cochrane Collaboration since 2007. The Cochrane Collaboration produces systematic reviews of the highest quality which have informed national and international guidelines for many conditions across medical specialties and form the basis of guidelines of the World Health Organisation. He is author of many systematic reviews with high international impact and informing WHO policies. He is expert advisor for the National Institute of Health and Care Excellence of the United Kingdom. He is a consultant paediatrician working for the Bedfordshire Hospitals NHS Foundation Trust in the United Kingdom. Due to his outstanding contributions he was made a Fellow of the Royal College of Paediatrics and Child Health and a Fellow of the Royal College of Physicians. Areas of clinical practice include treating children with eating disorders and urological conditions where one of the treatment modalities is increase in water intake. Amongst his more than 200 publications in peer reviewed journals across a wide range of topics are highly cited comprehensive analyses of nutritional interventions and the pathophysiology and pathogenesis of illness.
Dr. med. Michael Eisenhut has been an editor of the Cochrane Collaboration since 2007. The Cochrane Collaboration produces systematic reviews of the highest quality which have informed national and international guidelines for many conditions across medical specialties and form the basis of guidelines of the World Health Organisation. He is author of many systematic reviews with high international impact and informing WHO policies. He is expert advisor for the National Institute of Health and Care Excellence of the United Kingdom. He is a consultant paediatrician working for the Bedfordshire Hospitals NHS Foundation Trust in the United Kingdom. Due to his outstanding contributions he was made a Fellow of the Royal College of Paediatrics and Child Health and a Fellow of the Royal College of Physicians. Areas of clinical practice include treating children with eating disorders and urological conditions where one of the treatment modalities is increase in water intake. Amongst his more than 200 publications in peer reviewed journals across a wide range of topics are highly cited comprehensive analyses of nutritional interventions and the pathophysiology and pathogenesis of illness.
Research Keywords
Immunology, Infectious diseases, Inflammation, ion transport, eating disorders
Immunology, Infectious diseases, Inflammation, ion transport, eating disorders
Department of Human Pathology of Adult and Childhood, University of Messina, Messina, Italy
Research Keywords
Breast cancer; endometriosis; gestational diabetes; preterm birth; endometrial
Breast cancer; endometriosis; gestational diabetes; preterm birth; endometrial
Bio
Dr. Kenneth R. Butler, Jr. is a Professor of Pharmacology and Toxicology at the University of Mississippi Medical Center, with secondary appointments in Medicine and Population Health Science. With over 30 years of experience in biomedical research and education, his work focuses on chronic disease epidemiology, cardiovascular health, Alzheimer's disease, and health equity. Dr. Butler has authored numerous peer-reviewed publications and serves on editorial boards for several scientific journals. He is an elected Fellow of the American Heart Association and the Mississippi Academy of Sciences, and remains active in mentoring, teaching, and leading multidisciplinary research across institutions.
Dr. Kenneth R. Butler, Jr. is a Professor of Pharmacology and Toxicology at the University of Mississippi Medical Center, with secondary appointments in Medicine and Population Health Science. With over 30 years of experience in biomedical research and education, his work focuses on chronic disease epidemiology, cardiovascular health, Alzheimer's disease, and health equity. Dr. Butler has authored numerous peer-reviewed publications and serves on editorial boards for several scientific journals. He is an elected Fellow of the American Heart Association and the Mississippi Academy of Sciences, and remains active in mentoring, teaching, and leading multidisciplinary research across institutions.
Research Keywords
Chronic Disease Epidemiology, Alzheimer’s Disease and Related Dementias (ADRD), Cardiovascular Disease, Social Determinants of Health, Health Disparities, Community-Based Research, Aging and Cognitive Health, Translational Science, Bioethics, Artificial I
Chronic Disease Epidemiology, Alzheimer’s Disease and Related Dementias (ADRD), Cardiovascular Disease, Social Determinants of Health, Health Disparities, Community-Based Research, Aging and Cognitive Health, Translational Science, Bioethics, Artificial I
Department of Urology, Kameda Daiichi Hospital, Niigata City, Japan,
Division of Molecular Oncology, Department of Urology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Research Keywords
cancer biology; cell culture; cell signaling; cancer biomarkers; renal cell carcinoma; urothelial carcinoma
cancer biology; cell culture; cell signaling; cancer biomarkers; renal cell carcinoma; urothelial carcinoma
Keynote Speakers
Emeritus Professor of Medical Oncology, Department of Health Sciences, University of Florence, Florence, Italy
Bio
Prof. Mini is an Emeritus Professor of Medical Oncology at the Department of Health Sciences, University of Florence (Italy). His research interests comprise the mechanisms of tumor drug resistance, in particular to antimetabolites and metal-based drugs, cancer pharmacogenomics and pharmacogenetics, and controlled clinical trials in gastrointestinal cancers. His studies have contributed to the advancement of knowledge in the field of biochemical bases of anticancer drug synergism and molecular bases of anticancer drug resistance. Prof. Mini is the author of more than 190 original articles in international peer reviewed journals and about 80 reviews, editorials, book chapters, and letters. He has given over 260 invited talks at national and international conferences and seminars at Italian and foreign universities and has presented more than 350 communications at scientific congresses. In recognition of his outstanding achievements, Prof. Mini has received various awards and recognitions and grants for his research results, including the Leukemia Society of America Special Fellow Award in 1982, the Lady Tata Memorial Trust Award, the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award in 1988 and in 2019 the 'International Society of Antimicrobial Chemotherapy (ISAC) Fellow Award (London). Prof. Mini has also held prestigious positions in various scientific societies. He is currently the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology
Prof. Mini is an Emeritus Professor of Medical Oncology at the Department of Health Sciences, University of Florence (Italy). His research interests comprise the mechanisms of tumor drug resistance, in particular to antimetabolites and metal-based drugs, cancer pharmacogenomics and pharmacogenetics, and controlled clinical trials in gastrointestinal cancers. His studies have contributed to the advancement of knowledge in the field of biochemical bases of anticancer drug synergism and molecular bases of anticancer drug resistance. Prof. Mini is the author of more than 190 original articles in international peer reviewed journals and about 80 reviews, editorials, book chapters, and letters. He has given over 260 invited talks at national and international conferences and seminars at Italian and foreign universities and has presented more than 350 communications at scientific congresses. In recognition of his outstanding achievements, Prof. Mini has received various awards and recognitions and grants for his research results, including the Leukemia Society of America Special Fellow Award in 1982, the Lady Tata Memorial Trust Award, the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award in 1988 and in 2019 the 'International Society of Antimicrobial Chemotherapy (ISAC) Fellow Award (London). Prof. Mini has also held prestigious positions in various scientific societies. He is currently the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology
Research Keywords
Gastrointestinal Cancers; Tumor Drug Resistance; Cancer Pharmacogenomics and Pharmacogenetics; Anticancer Drug Synergism
Gastrointestinal Cancers; Tumor Drug Resistance; Cancer Pharmacogenomics and Pharmacogenetics; Anticancer Drug Synergism
Department of Biomedical Informatics and Center for Genomic Medicine, University of Utah Eccles School of Medicine, Salt Lake City, USA
Bio
Prof. Dr. Yves A. Lussier, MD, FAMIA, FACMI is Chair of Biomedical Informatics at the University of Utah School of Medicine. A professional engineer and physician-scientist, he is recognized internationally as a pioneer in translational bioinformatics, systems biology, and high-throughput approaches in personalized medicine. Previously, Prof. Dr. Lussier held leadership roles at the University of Arizona, where he directed the Center for Biomedical Informatics and Biostatistics, and at the University of Illinois and University of Chicago, advancing biomedical informatics, computational genomics, and precision health initiatives. His career began at Columbia University, where he was Assistant Professor of Biomedical Informatics and Medicine. With over 185 publications, 100 invited talks (including 28 international keynotes), and more than $190M in research funding, Prof. Dr. Lussier has made lasting contributions to data science–driven precision medicine. He has mentored over 90 trainees, many of whom have gone on to secure major awards and faculty positions. His honors include three IBM Faculty Awards, Fellowship in the American College of Medical Informatics, and an invitation to the White House Precision Medicine Summit.
Prof. Dr. Yves A. Lussier, MD, FAMIA, FACMI is Chair of Biomedical Informatics at the University of Utah School of Medicine. A professional engineer and physician-scientist, he is recognized internationally as a pioneer in translational bioinformatics, systems biology, and high-throughput approaches in personalized medicine. Previously, Prof. Dr. Lussier held leadership roles at the University of Arizona, where he directed the Center for Biomedical Informatics and Biostatistics, and at the University of Illinois and University of Chicago, advancing biomedical informatics, computational genomics, and precision health initiatives. His career began at Columbia University, where he was Assistant Professor of Biomedical Informatics and Medicine. With over 185 publications, 100 invited talks (including 28 international keynotes), and more than $190M in research funding, Prof. Dr. Lussier has made lasting contributions to data science–driven precision medicine. He has mentored over 90 trainees, many of whom have gone on to secure major awards and faculty positions. His honors include three IBM Faculty Awards, Fellowship in the American College of Medical Informatics, and an invitation to the White House Precision Medicine Summit.
Department of Orthopaedic Surgery, University of Tennessee Health Science Center, USA
Talk
Session 3: Diagnostics in Personalized Medicine We explored the capability of ChatGPT 4.0 in generating innovative research hypotheses to address key challenges in the early diagnosis of colorectal cancer (CRC). We asked ChatGPT to generate hypotheses focusing on three main challenges: improving screening accuracy, overcoming technological limitations, and identifying reliable biomarkers. The hypotheses were evaluated for novelty. The experimental plans provided by ChatGPT for selected hypotheses were assessed for completion and feasibility. As a result, ChatGPT generated a total of 65 hypotheses. ChatGPT rated all 65 hypotheses, with 25 hypotheses receiving the highest rating (5) and 40 hypotheses receiving a rating of 4 or lower. The research team evaluated a total of 65 hypotheses, assigning them the following grades: hypotheses were rated as excellent (Grade 5), 16 were deemed suitable (Grade 4), 31 were classified as satisfactory (Grade 3), 12 were identified as needing Improvement (Grade 2), and one was considered poor (Grade 1). Additionally, the study determined that 17 of the generated hypotheses had corresponding publications. Out of the three experimental plans assessed, one was rated excellent (5) for feasibility, while the others received good (4) and moderate (3) ratings. Predicted outcomes and alternative approaches were rated as good, with some areas requiring further improvement.
Session 3: Diagnostics in Personalized Medicine We explored the capability of ChatGPT 4.0 in generating innovative research hypotheses to address key challenges in the early diagnosis of colorectal cancer (CRC). We asked ChatGPT to generate hypotheses focusing on three main challenges: improving screening accuracy, overcoming technological limitations, and identifying reliable biomarkers. The hypotheses were evaluated for novelty. The experimental plans provided by ChatGPT for selected hypotheses were assessed for completion and feasibility. As a result, ChatGPT generated a total of 65 hypotheses. ChatGPT rated all 65 hypotheses, with 25 hypotheses receiving the highest rating (5) and 40 hypotheses receiving a rating of 4 or lower. The research team evaluated a total of 65 hypotheses, assigning them the following grades: hypotheses were rated as excellent (Grade 5), 16 were deemed suitable (Grade 4), 31 were classified as satisfactory (Grade 3), 12 were identified as needing Improvement (Grade 2), and one was considered poor (Grade 1). Additionally, the study determined that 17 of the generated hypotheses had corresponding publications. Out of the three experimental plans assessed, one was rated excellent (5) for feasibility, while the others received good (4) and moderate (3) ratings. Predicted outcomes and alternative approaches were rated as good, with some areas requiring further improvement.
Bio
Dr. Weikuan Gu, PhD, obtained his PhD from Cornell University. He is tenured and a full Professor in the Department of Orthopaedic Surgery and Biomedical Engineering. He is the Director of translational research in the department and the director of the DNA Discovery Core of the UTHSC Center of Genomics and Bioinformatics. Dr. Gu has a joint appointment in the Department of Pharmaceutics Sciences in the College of Pharmacy. He has published more than 140 peer reviewed full publications, more than 100 abstracts/ presentations/invited lectures, and 10 book chapters. He edited a book named “Gene Discovery for Disease Models”, which was published in early 2011. He also holds a patent for the identification of suitable patients for orally induced tolerance to arthritis and scleroderma. He served as a member of the editorial board for the Case report (during 2008 and 2010), Chinese Journal of Endemiology, Annals of Musculoskeletal Disorders, and the Journal of Personalized Medicine. He serves as a reviewer for 21 medical science journals. He has coordinated many collaborative international education and research activities. He has trained and/or coordinated the training of more than 100 people, including post-doctoral researchers, graduate students, summer students, and visiting scientists.
Dr. Weikuan Gu, PhD, obtained his PhD from Cornell University. He is tenured and a full Professor in the Department of Orthopaedic Surgery and Biomedical Engineering. He is the Director of translational research in the department and the director of the DNA Discovery Core of the UTHSC Center of Genomics and Bioinformatics. Dr. Gu has a joint appointment in the Department of Pharmaceutics Sciences in the College of Pharmacy. He has published more than 140 peer reviewed full publications, more than 100 abstracts/ presentations/invited lectures, and 10 book chapters. He edited a book named “Gene Discovery for Disease Models”, which was published in early 2011. He also holds a patent for the identification of suitable patients for orally induced tolerance to arthritis and scleroderma. He served as a member of the editorial board for the Case report (during 2008 and 2010), Chinese Journal of Endemiology, Annals of Musculoskeletal Disorders, and the Journal of Personalized Medicine. He serves as a reviewer for 21 medical science journals. He has coordinated many collaborative international education and research activities. He has trained and/or coordinated the training of more than 100 people, including post-doctoral researchers, graduate students, summer students, and visiting scientists.
Stanford Concierge and Executive Medicine, Stanford University, California, USA
Talk
The Science of Al in Pharmacogenomics: Transforming Precision Health and Personalized Care AI Meets Pharmacogenomics: Can Machine Learning Predict the Best Drug for You? The widespread adoption of pharmacogenomics (PGx)-based prescribing faces numerous implementation challenges, including clinician awareness, education, and resource constraints. Experts are now leveraging AI tools—including machine learning, large language models (LLMs), and generative AI—to advance pharmacogenomics research, clinical implementation, and decision support for healthcare providers. This keynote will explore real-world applications of AI-driven personalized prescribing, address risks such as algorithmic bias in AI-PGx tools, and outline emerging technologies and future directions. The session will conclude with a panel discussion on balancing innovation with caution, highlighting validated AI applications already in clinical workflows and areas where further testing and oversight are essential.
The Science of Al in Pharmacogenomics: Transforming Precision Health and Personalized Care AI Meets Pharmacogenomics: Can Machine Learning Predict the Best Drug for You? The widespread adoption of pharmacogenomics (PGx)-based prescribing faces numerous implementation challenges, including clinician awareness, education, and resource constraints. Experts are now leveraging AI tools—including machine learning, large language models (LLMs), and generative AI—to advance pharmacogenomics research, clinical implementation, and decision support for healthcare providers. This keynote will explore real-world applications of AI-driven personalized prescribing, address risks such as algorithmic bias in AI-PGx tools, and outline emerging technologies and future directions. The session will conclude with a panel discussion on balancing innovation with caution, highlighting validated AI applications already in clinical workflows and areas where further testing and oversight are essential.
Bio
Latha Palaniappan MD, MS, is an internist, and clinical and population researcher. Her research has focused on the study of diverse populations, chronic disease and prevention, and seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities. She was awarded a Stanford Impact Labs Leave in Service to pursue chronic disease prevention in India for Social Good. She is the Faculty co-Director of Stanford Biobank, designed to accelerate translatable scientific discoveries and co-founder for the Stanford Center for Asian American, Native Hawaiian and Pacific Islander Health Research and Education (CARE). CARE has established health related research collaborations in Asia, including student exchange programs in Hong Kong and Vietnam, and research collaborations in India, Japan, and Singapore. She has recently received a Fulbright Future Scholar Award and worked with the Commonwealth Scientific and Industrial Research Organization on implementation of Precision Health in Australia.
Latha Palaniappan MD, MS, is an internist, and clinical and population researcher. Her research has focused on the study of diverse populations, chronic disease and prevention, and seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities. She was awarded a Stanford Impact Labs Leave in Service to pursue chronic disease prevention in India for Social Good. She is the Faculty co-Director of Stanford Biobank, designed to accelerate translatable scientific discoveries and co-founder for the Stanford Center for Asian American, Native Hawaiian and Pacific Islander Health Research and Education (CARE). CARE has established health related research collaborations in Asia, including student exchange programs in Hong Kong and Vietnam, and research collaborations in India, Japan, and Singapore. She has recently received a Fulbright Future Scholar Award and worked with the Commonwealth Scientific and Industrial Research Organization on implementation of Precision Health in Australia.
Research Keywords
Pharmacogenomics (PgX); Implementation Science; Racial/Ethnic Minorities; Chronic Disease and Prevention; Cardiovascular Disease; Diabetes
Pharmacogenomics (PgX); Implementation Science; Racial/Ethnic Minorities; Chronic Disease and Prevention; Cardiovascular Disease; Diabetes
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
Bio
Dr Davide Barbagallo (DB) held a PhD in Biology, human genetics and bioinformatics in 2009 (supervisor: Prof. Michele Purrello), both from the University of Catania, Italy. From 2009 to 2019 DB carried on his research activity as PostDoc at University fo Catania, under the supervision of Prof. Michele Purrello. and Prof. Cinzia Di Pietro. In 2017 DB held specialization in medical genetics at University of Messina by discussing a thesis on the involvement of circular RNAs (circRNAs) in the pathogenesis of glioblastoma multiforme (GBM). His early studies were focused on the involvement of a set of transcripts belonging to the apoptotic machinery and to the class of microRNAs (miRNAs) in the etiology of diabetes mellitus. Since 2016, his scientific interests shifted towards the study of brain cancer, focusing on the involvement of miRNAs and circRNAs in its pathogenesis. DB collaborated to research activities on the involvement of non-coding RNAs in the field of human infertility and cancer. In 2017, thanks to the win of a travel grant sponsored by Umberto Veronesi Foundation, DB moved to Aarhus University (Denmark) where he learnt the main techniques to study the function of circRNAs and applied this knowledge to the study of functional involvement of circSMARCA5 in the pathogenesis of GBM, under the guidance of Dr. Thomas Hansen. DB has authored or co-authored more than 40 peer-reviewed scientific publications on impacted international journals, up today. Since 2020 DB is Assistant Professor of Applied Biology (SSD BIO/13) at University of Catania. Since 2023 DB is Associate Professor of Applied Biology (SSD BIO/13) at University of Catania.
Dr Davide Barbagallo (DB) held a PhD in Biology, human genetics and bioinformatics in 2009 (supervisor: Prof. Michele Purrello), both from the University of Catania, Italy. From 2009 to 2019 DB carried on his research activity as PostDoc at University fo Catania, under the supervision of Prof. Michele Purrello. and Prof. Cinzia Di Pietro. In 2017 DB held specialization in medical genetics at University of Messina by discussing a thesis on the involvement of circular RNAs (circRNAs) in the pathogenesis of glioblastoma multiforme (GBM). His early studies were focused on the involvement of a set of transcripts belonging to the apoptotic machinery and to the class of microRNAs (miRNAs) in the etiology of diabetes mellitus. Since 2016, his scientific interests shifted towards the study of brain cancer, focusing on the involvement of miRNAs and circRNAs in its pathogenesis. DB collaborated to research activities on the involvement of non-coding RNAs in the field of human infertility and cancer. In 2017, thanks to the win of a travel grant sponsored by Umberto Veronesi Foundation, DB moved to Aarhus University (Denmark) where he learnt the main techniques to study the function of circRNAs and applied this knowledge to the study of functional involvement of circSMARCA5 in the pathogenesis of GBM, under the guidance of Dr. Thomas Hansen. DB has authored or co-authored more than 40 peer-reviewed scientific publications on impacted international journals, up today. Since 2020 DB is Assistant Professor of Applied Biology (SSD BIO/13) at University of Catania. Since 2023 DB is Associate Professor of Applied Biology (SSD BIO/13) at University of Catania.
Department of Microbiology, Heersink School of Medicine, University of Alabama, Birmingham, AL, USA
Bio
Our research team is focused on creating a clinically relevant animal model to enhance our understanding of biology and develop new therapies for metastatic cancer and HIV-infected cells. Each model aims to investigate the complex mechanisms of cancer or HIV biology and their treatment effects at the molecular scale. Uncovering specific pathways has led to the emergence of new pharmaceuticals, such as antibody-drug conjugates, immunomodulators, and chimeric antigen receptors.
Our research team is focused on creating a clinically relevant animal model to enhance our understanding of biology and develop new therapies for metastatic cancer and HIV-infected cells. Each model aims to investigate the complex mechanisms of cancer or HIV biology and their treatment effects at the molecular scale. Uncovering specific pathways has led to the emergence of new pharmaceuticals, such as antibody-drug conjugates, immunomodulators, and chimeric antigen receptors.
Research Keywords
Cancer immunotherapy, HIV immunotherapy, CAR-T, CAR-Mac, bidirectional antibody, immunomodulator
Cancer immunotherapy, HIV immunotherapy, CAR-T, CAR-Mac, bidirectional antibody, immunomodulator
Bio
Dr. Taulant Muka is among the top 2% of the world’s most influential scientists, with over 180 peer-reviewed publications and extensive expertise in evidence-based medicine and public health. As CEO of Epistudia, he pioneers education innovation through AI and e-learning tools. Dr. Muka's academic journey spans prestigious institutions like University of Bern, Erasmus, Cambridge, Harvard, and Stanford, with research focusing on cardiometabolic health, sex differences, and evidence synthesis. His work has been featured in global media outlets like BBC, CNN, and The New York Times.
Dr. Taulant Muka is among the top 2% of the world’s most influential scientists, with over 180 peer-reviewed publications and extensive expertise in evidence-based medicine and public health. As CEO of Epistudia, he pioneers education innovation through AI and e-learning tools. Dr. Muka's academic journey spans prestigious institutions like University of Bern, Erasmus, Cambridge, Harvard, and Stanford, with research focusing on cardiometabolic health, sex differences, and evidence synthesis. His work has been featured in global media outlets like BBC, CNN, and The New York Times.
Research Keywords
evidence-based medicine; evidence synthesis; systematic reviews and meta-analyses; cardiometabolic health; sex differences in medicine; iron and estrogen; epidemiology; research methodology; healthcare Innovation; health disparities
evidence-based medicine; evidence synthesis; systematic reviews and meta-analyses; cardiometabolic health; sex differences in medicine; iron and estrogen; epidemiology; research methodology; healthcare Innovation; health disparities
Laboratory Medicine and Pathobiology; Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
Talk
1. History of Personalized Medicine Hippocrates, Galen, Morgagni – foundations of medical observation and diagnosis Garrod – discovery of alkaptonuria Meyer & Kalow – pioneers of pharmacogenetics and pharmacogenomics 2. Personalized Medicine Today – Focus on Individual Differences Intuition-based individual medicine Observation of unique patient characteristics Genetics Prenatal screening Phenylketonuria (PKU), Hypothyroidism Neonatal genetic screening Sporadic disease mechanisms RNA splicing Protein polymorphisms Local environment influences External factors Internal factors 3. Depersonalized Medicine – Emphasis on Similarities Observation of groups Evidence-based medicine Conventional statistics Precision medicine: accurate but sometimes missing the most important target Kuhn’s paradigm shift – rethinking frameworks Guidelines & reductionism Fragmented science Population health focus 4. Evolution and Future of Personalized Medicine Individual observation & therapy – returning to patient-centered care Seats of Disease – refining the understanding of where diseases arise Scientific methods – balancing commonalities and differences Population statistics Bell curve Outliers and inliers Pharmacogenetics Broadening vs. restricting the treatment label AI vs. Associative Enquiry Role of artificial intelligence in medicine Integration of science with clinical care Focused on individual patient needs as interpreted by physicians Critical interpretation of informatics tools by physicians and caregivers
1. History of Personalized Medicine Hippocrates, Galen, Morgagni – foundations of medical observation and diagnosis Garrod – discovery of alkaptonuria Meyer & Kalow – pioneers of pharmacogenetics and pharmacogenomics 2. Personalized Medicine Today – Focus on Individual Differences Intuition-based individual medicine Observation of unique patient characteristics Genetics Prenatal screening Phenylketonuria (PKU), Hypothyroidism Neonatal genetic screening Sporadic disease mechanisms RNA splicing Protein polymorphisms Local environment influences External factors Internal factors 3. Depersonalized Medicine – Emphasis on Similarities Observation of groups Evidence-based medicine Conventional statistics Precision medicine: accurate but sometimes missing the most important target Kuhn’s paradigm shift – rethinking frameworks Guidelines & reductionism Fragmented science Population health focus 4. Evolution and Future of Personalized Medicine Individual observation & therapy – returning to patient-centered care Seats of Disease – refining the understanding of where diseases arise Scientific methods – balancing commonalities and differences Population statistics Bell curve Outliers and inliers Pharmacogenetics Broadening vs. restricting the treatment label AI vs. Associative Enquiry Role of artificial intelligence in medicine Integration of science with clinical care Focused on individual patient needs as interpreted by physicians Critical interpretation of informatics tools by physicians and caregivers
Bio
Dr. Pritzker is Professor Emeritus in the Department of Laboratory Medicine and Pathobiology; Department of Surgery, Temerty Faculty of Medicine, and the Institute of Biomedical Engineering, University of Toronto and is Honorary Staff , Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto. Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto from 1986 to 2008. With over 290 scientific publications and 27 book chapters, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology. Dr. Pritzker served on the External Advisory Board, Institute of Microstructural Sciences, National Research Council of Canada, 2005-2011. Dr. Pritzker serves as editor-in-chief, Journal of Personalized Medicine.
Dr. Pritzker is Professor Emeritus in the Department of Laboratory Medicine and Pathobiology; Department of Surgery, Temerty Faculty of Medicine, and the Institute of Biomedical Engineering, University of Toronto and is Honorary Staff , Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto. Dr. Pritzker served as Chief, Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto from 1986 to 2008. With over 290 scientific publications and 27 book chapters, Ken is a recognized leader internationally in the fields of arthritis, biomaterials, genomics, cancer diagnostics and nanotechnology. Dr. Pritzker served on the External Advisory Board, Institute of Microstructural Sciences, National Research Council of Canada, 2005-2011. Dr. Pritzker serves as editor-in-chief, Journal of Personalized Medicine.
Invited Speaker
Prof. Dr. Jun Ishihara
Department of Bioengineering, Imperial College London, UK
Bio
Dr. Jun Ishihara is a Lecturer (Assistant Professor) in the Department of Bioengineering at Imperial College London, where his lab focuses on protein engineering for cancer immunotherapy, autoimmunity, and regenerative medicine. He received his PhD in stem cell biology from the University of Tokyo and completed postdoctoral training with Jeffrey Hubbell at EPFL and later at the University of Chicago. His research has led to novel immuno-engineering technologies, including localized cancer immunotherapies that enhance safety and efficacy, as well as engineered treatments for autoimmune diseases and innovative approaches to regenerative medicine. Dr. Ishihara has co-authored 25 papers and 16 patents in leading journals such as Nature Biomedical Engineering and Science Translational Medicine. He is also co-founder of Arrow Immune Inc., HeioThera Inc., and ScienceLounge LLC., advancing both clinical translation and public engagement in science.
Dr. Jun Ishihara is a Lecturer (Assistant Professor) in the Department of Bioengineering at Imperial College London, where his lab focuses on protein engineering for cancer immunotherapy, autoimmunity, and regenerative medicine. He received his PhD in stem cell biology from the University of Tokyo and completed postdoctoral training with Jeffrey Hubbell at EPFL and later at the University of Chicago. His research has led to novel immuno-engineering technologies, including localized cancer immunotherapies that enhance safety and efficacy, as well as engineered treatments for autoimmune diseases and innovative approaches to regenerative medicine. Dr. Ishihara has co-authored 25 papers and 16 patents in leading journals such as Nature Biomedical Engineering and Science Translational Medicine. He is also co-founder of Arrow Immune Inc., HeioThera Inc., and ScienceLounge LLC., advancing both clinical translation and public engagement in science.
School of Medicine, University of Mississippi Medical Center, Jackson, USA
Department of Molecular and Precision Medicine, Pennsylvania State College of Medicine, Hershey, PA, USA
Talk
The “Whole Human” concept for the future of Personalized Medicine. Understanding and management of “Whole human“ for personalized medicine will influence the future for precision care. The biochemical pathways leading to breakdown as well as building up of basic components required for proper functioning of human body could help create individualized models with the help of machine learning tools. The Perturbations in our daily lives such as aging, stress, life style choices, environment and occasional mutations could impact the biochemical pathways at the cellular level that point to abnormalities and eventually contribute to a diseased state. Studying the whole human from head to toe based on these biochemical pathways in part, could assist in developing the framework for monitoring and observing changes overtime and provide personalized attention to the abnormal state. Constant monitoring through wearable devices could help maintain a balanced lifestyle. Correcting abnormalities one at a time, such as deficiency in a vitamin could resolve that issue, determining the senescence in cells within or around adipose tissue could shed light on understanding causes of obesity, and following the growth promoting signals may influence the cellular architecture to form cancer. Ultimately, with the help of our overall knowledge of the body any perturbations could be monitored and issues such as drug sensitivity, drug interactions, and drug response rate could be monitored and managed. In addition, cause(s) of the disease(s) could be modeled, and potential prevention and therapy strategy could be invested as an efficient individualized plan. Using the ‘whole human’ for personalized medicine is feasible in the near future, and we need to begin working as a team to quickly streamline the process involving scientists, engineers, system biologists, bioinformaticians, statisticians and clinicians at a global level without worrying about fame and funds! Let us discuss an open strategy to achieve and disperse personalized medicine based on the ‘whole human’ concept.
The “Whole Human” concept for the future of Personalized Medicine. Understanding and management of “Whole human“ for personalized medicine will influence the future for precision care. The biochemical pathways leading to breakdown as well as building up of basic components required for proper functioning of human body could help create individualized models with the help of machine learning tools. The Perturbations in our daily lives such as aging, stress, life style choices, environment and occasional mutations could impact the biochemical pathways at the cellular level that point to abnormalities and eventually contribute to a diseased state. Studying the whole human from head to toe based on these biochemical pathways in part, could assist in developing the framework for monitoring and observing changes overtime and provide personalized attention to the abnormal state. Constant monitoring through wearable devices could help maintain a balanced lifestyle. Correcting abnormalities one at a time, such as deficiency in a vitamin could resolve that issue, determining the senescence in cells within or around adipose tissue could shed light on understanding causes of obesity, and following the growth promoting signals may influence the cellular architecture to form cancer. Ultimately, with the help of our overall knowledge of the body any perturbations could be monitored and issues such as drug sensitivity, drug interactions, and drug response rate could be monitored and managed. In addition, cause(s) of the disease(s) could be modeled, and potential prevention and therapy strategy could be invested as an efficient individualized plan. Using the ‘whole human’ for personalized medicine is feasible in the near future, and we need to begin working as a team to quickly streamline the process involving scientists, engineers, system biologists, bioinformaticians, statisticians and clinicians at a global level without worrying about fame and funds! Let us discuss an open strategy to achieve and disperse personalized medicine based on the ‘whole human’ concept.
Bio
Raghu Sinha, PhD is a Professor of Molecular and Precision Medicine, Penn State College of Medicine, Hershey, Pennsylvania. He is an expert in cancer chemoprevention, cancer therapy and proteomics. His research focuses on studying mechanisms of breast, prostate and pancreatic tumor growth inhibition by organoselenium compounds, impact of dietary sulfur amino acids in animal cancer models and healthy humans, effects of tobacco products on lung epithelial cells, cancer systems biology, protein-protein interactions, and multi-omics approaches for identifying diagnostic and prognostic cancer biomarkers as well as drug repurposing strategies. He has mentored high school, undergraduate and graduate students, and post-doctoral fellows.
Raghu Sinha, PhD is a Professor of Molecular and Precision Medicine, Penn State College of Medicine, Hershey, Pennsylvania. He is an expert in cancer chemoprevention, cancer therapy and proteomics. His research focuses on studying mechanisms of breast, prostate and pancreatic tumor growth inhibition by organoselenium compounds, impact of dietary sulfur amino acids in animal cancer models and healthy humans, effects of tobacco products on lung epithelial cells, cancer systems biology, protein-protein interactions, and multi-omics approaches for identifying diagnostic and prognostic cancer biomarkers as well as drug repurposing strategies. He has mentored high school, undergraduate and graduate students, and post-doctoral fellows.
Research Keywords
chemoprevention, cancer diagnostics, cancer therapy, oxidative stress, proteomics, systems biology
chemoprevention, cancer diagnostics, cancer therapy, oxidative stress, proteomics, systems biology
Talk
Title: Beyond the Genome: Integrative Strategies for Personalized Cancer Therapy Tentative abstract: Recent advances in precision oncology have expanded the boundaries of personalized cancer treatment beyond the genomic landscape. While genomic alterations have traditionally guided targeted therapies, many cases lack actionable mutations or present complex heterogeneity. In such contexts, transcriptome-based analyses offer valuable insights into the functional state of tumors. RNA-seq-derived pathway activity scores have proven effective in nominating druggable pathways, even when mutation data are inconclusive. Furthermore, patient-derived organoids (PDOs) have emerged as powerful ex vivo platforms for assessing drug sensitivity. These models not only recapitulate tumor heterogeneity but also demonstrate a high concordance with clinical treatment outcomes, offering a valuable tool for individualized therapy selection. In parallel, circulating tumor cells (CTCs) are gaining ground as minimally invasive liquid biopsy tools. CTC-based analyses allow for real-time monitoring of treatment response, with CTC enumeration correlating strongly with therapeutic efficacy. Moreover, molecular profiling of CTCs—through both DNA sequencing and immunohistochemistry—provides diagnostic and prognostic insights. This talk will present an integrative perspective on the evolving toolkit of personalized cancer therapy, highlighting case examples from our lab where transcriptomics, organoid-based drug testing, and CTC analysis have informed precise and effective treatment strategies.
Title: Beyond the Genome: Integrative Strategies for Personalized Cancer Therapy Tentative abstract: Recent advances in precision oncology have expanded the boundaries of personalized cancer treatment beyond the genomic landscape. While genomic alterations have traditionally guided targeted therapies, many cases lack actionable mutations or present complex heterogeneity. In such contexts, transcriptome-based analyses offer valuable insights into the functional state of tumors. RNA-seq-derived pathway activity scores have proven effective in nominating druggable pathways, even when mutation data are inconclusive. Furthermore, patient-derived organoids (PDOs) have emerged as powerful ex vivo platforms for assessing drug sensitivity. These models not only recapitulate tumor heterogeneity but also demonstrate a high concordance with clinical treatment outcomes, offering a valuable tool for individualized therapy selection. In parallel, circulating tumor cells (CTCs) are gaining ground as minimally invasive liquid biopsy tools. CTC-based analyses allow for real-time monitoring of treatment response, with CTC enumeration correlating strongly with therapeutic efficacy. Moreover, molecular profiling of CTCs—through both DNA sequencing and immunohistochemistry—provides diagnostic and prognostic insights. This talk will present an integrative perspective on the evolving toolkit of personalized cancer therapy, highlighting case examples from our lab where transcriptomics, organoid-based drug testing, and CTC analysis have informed precise and effective treatment strategies.
Bio
Dr. Kazim Yalcin Arga received his Diploma (B.Sc.) and Doctorate (Ph.D.) in Chemical Engineering from Bogazici University (Istanbul), in 2001 and 2007, respectively. He is currently Professor at the Bioengineering Department of Marmara University since September 2007. His current research under the Systems Bioengineering research group focuses on integrating functional genomics data with biological networks via mathematical and statistical models to optimize production capabilities of yeast, bacteria and extremophiles, and to identify reporter biomarkers for complex human diseases. He is currently the vice head of the Bioengineering Department and gives several mathematical modeling, bioinformatics and systems biology courses at undergraduate and graduate programs of Marmara University. Dr. Kazim Yalcin Arga is the author of many scientific articles in peer-reviewed journals and is active referee of many systems biology and bioinformatics journals.
Dr. Kazim Yalcin Arga received his Diploma (B.Sc.) and Doctorate (Ph.D.) in Chemical Engineering from Bogazici University (Istanbul), in 2001 and 2007, respectively. He is currently Professor at the Bioengineering Department of Marmara University since September 2007. His current research under the Systems Bioengineering research group focuses on integrating functional genomics data with biological networks via mathematical and statistical models to optimize production capabilities of yeast, bacteria and extremophiles, and to identify reporter biomarkers for complex human diseases. He is currently the vice head of the Bioengineering Department and gives several mathematical modeling, bioinformatics and systems biology courses at undergraduate and graduate programs of Marmara University. Dr. Kazim Yalcin Arga is the author of many scientific articles in peer-reviewed journals and is active referee of many systems biology and bioinformatics journals.
Department of Neurosciences, Imaging and Clinical Sciences, Universita G. D'Annunzio Chieti-Pescara, Chieti, Italy
Talk
Methodologies and Applications in Pharmacogenetics for Precision Medicine
Methodologies and Applications in Pharmacogenetics for Precision Medicine
Bio
Dr. Nobili is Assistant Professor in Pharmacology at the Department of Neuroscience Psychology Pharmacology and Child Health of the University of Florence (Italy). She received her Pharm.D. degree from the University of Rome ‘La Sapienza’ in 1989, her specialization in Applied Pharmacology from the University of Florence in 1997, and her Ph.D. in Chemotherapy from the University of Milan in 2001. In 2013, she was awarded the Alberico Benedicenti Award for Pharmacology and Toxicology from the Italian Society of Pharmacology. She worked as Assistant Professor in Pharmacology from 2007 to 2019 at the University of Florence (Italy) and from 2020 to 2022 at the "G. D'Annunzio" University of Chieti Pescara (Italy). Her research interests are focused on preclinical and clinical pharmacology of anticancer drugs, in particular cancer pharmacogenetics and pharmacogenomics, tumor drug resistance, with emphasis on drugs used in the treatment of gastrointestinal neoplasms.
Dr. Nobili is Assistant Professor in Pharmacology at the Department of Neuroscience Psychology Pharmacology and Child Health of the University of Florence (Italy). She received her Pharm.D. degree from the University of Rome ‘La Sapienza’ in 1989, her specialization in Applied Pharmacology from the University of Florence in 1997, and her Ph.D. in Chemotherapy from the University of Milan in 2001. In 2013, she was awarded the Alberico Benedicenti Award for Pharmacology and Toxicology from the Italian Society of Pharmacology. She worked as Assistant Professor in Pharmacology from 2007 to 2019 at the University of Florence (Italy) and from 2020 to 2022 at the "G. D'Annunzio" University of Chieti Pescara (Italy). Her research interests are focused on preclinical and clinical pharmacology of anticancer drugs, in particular cancer pharmacogenetics and pharmacogenomics, tumor drug resistance, with emphasis on drugs used in the treatment of gastrointestinal neoplasms.
Hellenic Pasteur Institute, Athens, Greece AND University of Patras, School of Health Sciences, Department of Pharmacy, Patras, Greece,
Laboratory of Pharmacogenomics and Individualized Therapy, Department of Pharmacy, School of Health Sciences, University of Patras, Patras, Greece
Talk
Precision Psychiatry
Precision Psychiatry
Bio
Dr. George P. Patrinos is a Professor of Pharmacogenomics and Pharmaceutical Biotechnology at the Department of Pharmacy, University of Patras, Greece. He obtained a B.Sc. in Biology and a Ph.D. in Molecular Biology from the University of Athens. His research interests include pharmacogenomics, personalized medicine and therapeutics, clinical care, clinical implementation, clinical studies, genome informatics, health technology assessments, and regulatory guidance.
Dr. George P. Patrinos is a Professor of Pharmacogenomics and Pharmaceutical Biotechnology at the Department of Pharmacy, University of Patras, Greece. He obtained a B.Sc. in Biology and a Ph.D. in Molecular Biology from the University of Athens. His research interests include pharmacogenomics, personalized medicine and therapeutics, clinical care, clinical implementation, clinical studies, genome informatics, health technology assessments, and regulatory guidance.
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
Talk
Germline Pharmacogenetics as a Tool to Prevent Cancer Drug Adverse Reactions
Germline Pharmacogenetics as a Tool to Prevent Cancer Drug Adverse Reactions
Bio
Erika Cecchin is a researcher of the Clinical and Experimental Pharmacology Unit, of CRO- Aviano where she works on the pharmacogenetic research for the optimization of the chemotherapeutic treatment in cancer. She is author of several full-length publications in international peer reviewed journals and chapters in international books. In 2010 she has been awarded with the “Guido Berlucchi Foundation” prize for young researchers. She is a member of the scientific board of a recently constituted CRO spin-off (PharmaDIAGEN), with the mission to perform pharmacogenetic research and to integrate it in the clinical practice, by the production of commercial pharmacogenetic/ genomic diagnostic kits. Main focus of her researches is the identification of innovative approaches for tailoring anti-cancer treatments based on the genetic characteristics of the patients. The major objective of her studies is to deeply understand the role of genetic markers (polymorphisms) involved in the pharmacokinetics and pharmacodynamics of anti-cancer drugs and to translate such knowledge into the clinical setting, to improve the pharmacological intervention in cancer treatment.
Erika Cecchin is a researcher of the Clinical and Experimental Pharmacology Unit, of CRO- Aviano where she works on the pharmacogenetic research for the optimization of the chemotherapeutic treatment in cancer. She is author of several full-length publications in international peer reviewed journals and chapters in international books. In 2010 she has been awarded with the “Guido Berlucchi Foundation” prize for young researchers. She is a member of the scientific board of a recently constituted CRO spin-off (PharmaDIAGEN), with the mission to perform pharmacogenetic research and to integrate it in the clinical practice, by the production of commercial pharmacogenetic/ genomic diagnostic kits. Main focus of her researches is the identification of innovative approaches for tailoring anti-cancer treatments based on the genetic characteristics of the patients. The major objective of her studies is to deeply understand the role of genetic markers (polymorphisms) involved in the pharmacokinetics and pharmacodynamics of anti-cancer drugs and to translate such knowledge into the clinical setting, to improve the pharmacological intervention in cancer treatment.
Talk
Personalized Biomarkers for Diagnosis and Theragnosis of Malignant Serous Effusions
Personalized Biomarkers for Diagnosis and Theragnosis of Malignant Serous Effusions
Department of Physiology and Cell Biology, University of Nevada, Reno, United States
Talk
Decoding Gastroparesis: A Paradigm Shift to Precision Pathophysiology & Therapy
Decoding Gastroparesis: A Paradigm Shift to Precision Pathophysiology & Therapy
Bio
Dr. Rajan Singh is an Assistant Professor (Research) at the University of Nevada, Reno School of Medicine, specializing in Neurogastroenterology and Motility. He earned his Ph.D. from the GI Motility and Pathophysiology Lab at Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. His research focuses on the cellular pathogenesis and molecular mechanisms of disorders of gut–brain interactions (DGBIs), including functional dyspepsia, irritable bowel syndrome (IBS), and idiopathic and diabetic gastroparesis. He investigates how defects in gastrointestinal cells contribute to these disorders, with particular attention to gut dysmotility, intestinal barrier dysfunction, and gut immune dysfunction—the core pathophysiological mechanisms of DGBIs. Dr. Singh is passionate about advancing understanding of these pathologies and believes that targeting the underlying cellular defects offers the most promising therapeutic approach for treating DGBIs in the future.
Dr. Rajan Singh is an Assistant Professor (Research) at the University of Nevada, Reno School of Medicine, specializing in Neurogastroenterology and Motility. He earned his Ph.D. from the GI Motility and Pathophysiology Lab at Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. His research focuses on the cellular pathogenesis and molecular mechanisms of disorders of gut–brain interactions (DGBIs), including functional dyspepsia, irritable bowel syndrome (IBS), and idiopathic and diabetic gastroparesis. He investigates how defects in gastrointestinal cells contribute to these disorders, with particular attention to gut dysmotility, intestinal barrier dysfunction, and gut immune dysfunction—the core pathophysiological mechanisms of DGBIs. Dr. Singh is passionate about advancing understanding of these pathologies and believes that targeting the underlying cellular defects offers the most promising therapeutic approach for treating DGBIs in the future.
Registration
The registration for IOCPM 2025 will be free of charge! The registration includes attendance to all conference sessions.
If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.
Please note that the submission and registration are two separate parts. Only scholars who registered can receive a link to access the conference live streaming. The deadline for registration is 24 October 2025.
Instructions for Authors
Procedure for Submission
IOCPM 2025 will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
Important Deadlines
Deadline for abstract submission: 11 August 2025
Deadline for abstract acceptance notification: 12 September 2025. You will be notified of the acceptance of an oral presentation in a separate email.
Deadline for abstract acceptance notification: 12 September 2025. You will be notified of the acceptance of an oral presentation in a separate email.
Certificates of Participation are available in your logged-in area of Sciforum.net, under “My Certificates” after the conference. Please note that the certificate is only for authors with accepted abstracts or registrations who attend the live session.
Abstract submissions
Abstract submissions should be completed online by registering with www.sciforum.net and using the "Submit Abstract" function on conference homepage. No physical template is necessary.
1. The abstract structure should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
2. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
3. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
4. The abstracts submitted to this conference must be original and novel, without prior publication in any journals or it will not be accepted to this conference.
1. The abstract structure should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
2. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
3. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
4. The abstracts submitted to this conference must be original and novel, without prior publication in any journals or it will not be accepted to this conference.
Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
Oral Presentation and Slides Submission
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session. Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the abstract. Slides, if available, will be displayed directly on the website using the proprietary slide viewer at Sciforum.net.
Poster Presentation
All accepted posters will be permanently exhibited online in the Poster Gallery.
- Should include the title, authors, contact details and main research findings, as well as tables, figures and graphs where necessary.
- Size in pixel: 1080 width x 1536 height–portrait orientation.
- Size in cm: 38,1 width x 54,2 height–portrait orientation.
- Font size: ≥16.
- Examples of successful submissions can be viewed here at the following links: (1), (2), (3)
- You can use our free template to create your poster. The poster template can be downloaded HERE.
- Size in pixel: 1080 width x 1536 height–portrait orientation.
- Size in cm: 38,1 width x 54,2 height–portrait orientation.
- Font size: ≥16.
- Examples of successful submissions can be viewed here at the following links: (1), (2), (3)
- You can use our free template to create your poster. The poster template can be downloaded HERE.
We will reach out to you closer to the dates of the conference with more information.
Potential Conflicts of Interest
It is the author's responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunity
1. Journal of Personalized Medicine Journal Publication
Participants in this conference are cordially invited to contribute a full manuscript to a Special Issue published in Journal of Personalized Medicine (ISSN: 2075-4426), with a 20% discount on the publication fee. Please note if you have IOAP/association discounts, conference discounts will be combined with IOAP/association discounts. Conference discounts cannot be combined with reviewer vouchers or any other vouchers. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
Participants in this conference are cordially invited to contribute a full manuscript to a Special Issue published in Journal of Personalized Medicine (ISSN: 2075-4426), with a 20% discount on the publication fee. Please note if you have IOAP/association discounts, conference discounts will be combined with IOAP/association discounts. Conference discounts cannot be combined with reviewer vouchers or any other vouchers. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
2. Proceeding Paper Publication
All accepted abstracts will be published in the conference report of IOCPM 2025 in Medical Sciences Forum (ISSN: 2673-9992) after quality check. If you wish to publish an extended proceeding paper (4–8 pages), please submit it to the same journal after the conference.
All accepted abstracts will be published in the conference report of IOCPM 2025 in Medical Sciences Forum (ISSN: 2673-9992) after quality check. If you wish to publish an extended proceeding paper (4–8 pages), please submit it to the same journal after the conference.
Authors are asked to disclose that it is a proceeding paper of the IOCPM 2025 conference paper in their cover letter. Carefully read the rules outlined in the 'Instructions for Authors' on the journal’s website and ensure that your submission adheres to these guidelines.
Proceedings paper submission deadline: 15 December 2025.
Manuscripts for the proceedings issue must be formatted as follows:
Title;
Full author names;
Affiliations (including full postal address) and authors' e-mail addresses;
Abstract;
Keywords;
Introduction;
Methods;
Results and Discussion;
Conclusions;
Acknowledgments;
Title;
Full author names;
Affiliations (including full postal address) and authors' e-mail addresses;
Abstract;
Keywords;
Introduction;
Methods;
Results and Discussion;
Conclusions;
Acknowledgments;
References.
Medical Science Proceeding Template.docx
Event Awards
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide 4 awards including the Best Oral Presentation Award and Best Poster Award.
The Awards
Best Oral Presentation Award and Best Poster Award
There will be 4 winners selected for these awards. The winner will receive a certificate and 200 CHF each.
Number of Awards Available: 4
The Best Oral Presentation Award is given to the paper judged to make the most significant oral contribution to the conference.
The Best Poster Award is given to the submission judged to make the most significant and interesting poster for the conference.
There will be 4 winners selected for these awards. The winner will receive a certificate and 200 CHF each.
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Media Partners
Conference Secretariat
Ms. Fionn Ee
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
